RPGLIFE RPG Life Sciences Q4 FY26 results (Jan–Mar 2026) and concall
RPG Life Sciences delivered a robust Q4 FY26, driven by strong domestic formulation growth that significantly outpaced the market. The API segment showed a strong recovery, contributing to overall profitability despite earlier disruptions. While international formulations faced temporary headwinds, the company maintains a strong balance sheet and is actively pursuing both organic and inorganic growth opportunities, focusing on quality and execution excellence.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 23.8%, net profit down 74.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 172 | 173 | 143 | 169 | 182 +6% | 180 +4% | 177 +24% |
| EBITDA | 46 | 49 | 25 | 35 | 39 −15% | 40 −18% | 33 +32% |
| Net profit | 4 | 35 | 117 | 26 | 37 +825% | 22 −37% | 30 −74% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
